![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, April 09, 2013 8:10:19 PM
ISEV 2013 Boston 12th Annual Frye Halloran -
The Educational Symposium of ISEV
EXOSOMES AND THE NERVOUS SYSTEM: MOLECULAR BIOLOGY, DIAGNOSIS AND THERAPEUTIC IMPLICATIONS
Massachusetts General Hospital - April 16, 2013
The Frye - Halloran Symposium is an annual event that aims to facilitate the transition of promising innovations from the laboratory to the care of the patient. Noteworthy past symposia have included the introduction of micro dialysis for real-time in situ measurement of activated drugs, the identification of novel MRI signal changes as markers of the effect of angiogenesis inhibitors, the development of therapies based upon viral vectors and cell-based immunizations, and racial diversity in glioma patient populations. This past conference led to the identification of IDH1 mutations as biomarkers for the diagnosis of brain tumors.
The 2013 symposium, taking place at the Massachusetts General Hospital on April 16, brings together international exosome experts to address the molecular revolution by which cell derived microparticles can provide diagnosis of gliomas, can be used to biomark for response and prognosis and offer the possibility of novel therapeutics. With the identification of glioma specific recurrent mutations in the last 5 years, we are now on the cusp of translating these molecular discoveries into meaningful clinical strategies for patient care. Exosome studies will play a major role in these advances. The symposium will provide clinicians with a working understanding of this emerging field, set the stage for upcoming clinical trials and opportunities for collaboration. Most importantly observations linking exosomes to the nervous system can be extrapolated to a wider range of infectious diseases and immunologic control mechanisms.
The one day Frye Halloran Educational Symposium will be divided into 3 sessions:
Session 1: Definitions and Basic Understanding of Exosomes and Extracellular MicroVesicles
Session 2: Application of Analytics to the Identification of Exosomes in Biofluids
Session 3: Clinical Diagnostic and Therapeutic Studies of Exosomes in the Nervous System
We envision the meeting to be of interest to clinicians and laboratory scientists in the fields of neurology, neuro-oncology, neurosurgery, neuropathology, radiation oncology, neuroradiology, nursing and other specialties involved in the research, diagnosis, care and treatment of patients with neurological conditions.
http://www.frye-halloran.org/
Recent AEMD News
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/17/2024 04:15:21 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/15/2024 01:27:15 PM
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering • PR Newswire (US) • 05/15/2024 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/13/2024 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:01:40 PM
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma • PR Newswire (US) • 05/10/2024 12:01:00 PM
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:15:39 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM